- Home
- NXTC vs MNY Comparison
NXTC vs MNY Comparison
Compare NXTC & MNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- MNY
- Stock Information
- Founded
- NXTC 2015
- MNY 2014
- Country
- NXTC United States
- MNY Singapore
- Employees
- NXTC N/A
- MNY N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- MNY
- Sector
- NXTC Health Care
- MNY
- Exchange
- NXTC Nasdaq
- MNY Nasdaq
- Market Cap
- NXTC 40.3M
- MNY 43.4M
- IPO Year
- NXTC 2019
- MNY N/A
- Fundamental
- Price
- NXTC $1.31
- MNY $1.18
- Analyst Decision
- NXTC Strong Buy
- MNY
- Analyst Count
- NXTC 2
- MNY 0
- Target Price
- NXTC $4.00
- MNY N/A
- AVG Volume (30 Days)
- NXTC 44.0K
- MNY 94.4K
- Earning Date
- NXTC 11-07-2024
- MNY 12-04-2024
- Dividend Yield
- NXTC N/A
- MNY N/A
- EPS Growth
- NXTC N/A
- MNY N/A
- EPS
- NXTC N/A
- MNY N/A
- Revenue
- NXTC N/A
- MNY $88,966,855.00
- Revenue This Year
- NXTC N/A
- MNY $26.64
- Revenue Next Year
- NXTC N/A
- MNY $25.46
- P/E Ratio
- NXTC N/A
- MNY N/A
- Revenue Growth
- NXTC N/A
- MNY 28.71
- 52 Week Low
- NXTC $1.03
- MNY $0.76
- 52 Week High
- NXTC $2.57
- MNY $4.70
- Technical
- Relative Strength Index (RSI)
- NXTC 45.61
- MNY 53.38
- Support Level
- NXTC $1.30
- MNY $1.12
- Resistance Level
- NXTC $1.60
- MNY $1.29
- Average True Range (ATR)
- NXTC 0.08
- MNY 0.09
- MACD
- NXTC 0.00
- MNY 0.00
- Stochastic Oscillator
- NXTC 12.12
- MNY 52.17
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.